Caroline Seynaeve
About
Caroline Seynaeve is a scholar working on Genetics, Cancer Research and Oncology.
According to data from OpenAlex, Caroline Seynaeve has authored 189 papers receiving a total of 9.4k indexed citations (citations by other indexed papers that have themselves been cited), including 119 papers in Genetics, 86 papers in Cancer Research and 81 papers in Oncology. Recurrent topics in Caroline Seynaeve's work include BRCA gene mutations in cancer (77 papers), Breast Cancer Treatment Studies (61 papers) and Estrogen and related hormone effects (45 papers). Caroline Seynaeve is often cited by papers focused on BRCA gene mutations in cancer (77 papers), Breast Cancer Treatment Studies (61 papers) and Estrogen and related hormone effects (45 papers). Caroline Seynaeve collaborates with scholars based in Netherlands, United Kingdom and United States. Caroline Seynaeve's co-authors include Cecile T.M. Brekelmans, Jan G.M. Klijn, Sanne B. Schagen, Willem Boogerd, Marian B. E. Menke‐Pluymers, E.J. Meijers-Heijboer, Vincent Koppelmans, Monique M.B. Breteler, J.G.M. Klijn and L.C. Verhoog and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.
In The Last Decade
Caroline Seynaeve
188 papers receiving 9.1k citations
Hit Papers
Peers
Caroline Seynaeve
Nadine Tung United States
Jennifer K. Litton United States
Claudine Isaacs United States
Lisa Cannon‐Albright United States
Patrick Neven Belgium
Ellen Warner Canada
Kathleen E. Malone United States
Carl Blomqvist Finland
Lucia Del Mastro Italy
Tommy� Fornander Sweden
Citations per year, relative to Caroline Seynaeve Caroline Seynaeve (= 1×)
peers
Nadine Tung
Countries citing papers authored by Caroline Seynaeve
Since
Specialization
Citations
This map shows the geographic impact of Caroline Seynaeve's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caroline Seynaeve with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caroline Seynaeve more than expected).
Fields of papers citing papers by Caroline Seynaeve
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Caroline Seynaeve. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caroline Seynaeve. The network helps show where Caroline Seynaeve may publish in the future.
Co-authorship network of co-authors of Caroline Seynaeve
This figure shows the co-authorship network connecting the top 25 collaborators of Caroline Seynaeve. A scholar is included among the top collaborators of Caroline Seynaeve based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caroline Seynaeve. Caroline Seynaeve is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Geurts-Giele, Willemina R.R., Carolien H. M. van Deurzen, P. J. van Diest, et al.. (2016). Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant. Modern Pathology. 30(1). 15–25.
2.
Heemskerk-Gerritsen, B.A.M., Caroline Seynaeve, C. J. van Asperen, et al.. (2015). Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction. JNCI Journal of the National Cancer Institute. 107(5).
3.
Engels, C.C., Nienke A. de Glas, Anita Sajet, et al.. (2015). The influence of insulin‐like Growth Factor‐1‐Receptor expression and endocrine treatment on clinical outcome of postmenopausal hormone receptor positive breast cancer patients: A Dutch TEAM substudy analysis. Molecular Oncology. 10(4). 509–516.
4.
Heemskerk-Gerritsen, B.A.M., Matti A. Rookus, Cora M. Aalfs, et al.. (2014). Improved overall survival after contralateral risk‐reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis. International Journal of Cancer. 136(3). 668–677.
5.
Heemskerk-Gerritsen, B.A.M., Rob B. van der Luijt, Inge-Marie Obdeijn, et al.. (2014). Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingo-oophorectomy. Cancer Biology & Therapy. 15(4). 371–379.
6.
Brohet, Richard M., Frans B.L. Hogervorst, Hanne Meijers‐Heijboer, et al.. (2013). Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. Journal of Medical Genetics. 51(2). 98–107.
7.
Koppelmans, Vincent, Monique M.B. Breteler, Willem Boogerd, Caroline Seynaeve, & Sanne B. Schagen. (2013). Late effects of adjuvant chemotherapy for adult onset non-CNS cancer; cognitive impairment, brain structure and risk of dementia. Critical Reviews in Oncology/Hematology. 88(1). 87–101.
8.
Water, W. van de, Christos Markopoulos, Cornelis J.�H. van de Velde, et al.. (2012). Association Between Age at Diagnosis and Disease-Specific Mortality Among Postmenopausal Women With Hormone Receptor–Positive Breast Cancer. Obstetrical & Gynecological Survey. 67(7). 415–416.
9.
Saadatmand, Sepideh, Emiel J. Rutgers, Linetta B. Koppert, et al.. (2012). Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial. BMC Cancer. 12(1). 440–440.
10.
Water, W. van de, D.B.Y. Fontein, Johanna G. H. van Nes, et al.. (2012). Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer – A TEAM study analysis. European Journal of Cancer. 49(2). 297–304.
11.
Water, W. van de, Esther Bastiaannet, E.T.M. Hille, et al.. (2011). Age-Specific Nonpersistence of Endocrine Therapy in Postmenopausal Patients Diagnosed with Hormone Receptor–Positive Breast Cancer: A TEAM Study Analysis. The Oncologist. 17(1). 55–63.
12.
Velde, Cornelis JH van de, Daniel Rea, Caroline Seynaeve, et al.. (2011). Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. The Lancet. 377(9762). 321–331.
13.
Bartlett, John M.S., Cassandra Brookes, Tammy Robson, et al.. (2011). Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial. Journal of Clinical Oncology. 29(12). 1531–1538.
14.
Hollestelle, Antoinette, Maartje J. Hooning, Ellen Crepin, et al.. (2010). Prevalence of the variant allele rs61764370 T>G in the 3′UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families. Breast Cancer Research and Treatment. 128(1). 79–84.
15.
Nes, Johanna G. H. van, Caroline Seynaeve, E. Maartense, et al.. (2009). Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. Annals of Oncology. 21(5). 974–982.
16.
Gool, Arthur R. Van, Caroline Seynaeve, H.J. Duivenvoorden, et al.. (2007). Who is prone to high levels of distress after prophylactic mastectomy and/or salpingo-ovariectomy?. Annals of Oncology. 18(10). 1641–1645.
17.
Brekelmans, Cecile T.M., Caroline Seynaeve, M. Menke-Pluymers, et al.. (2005). Survival and prognostic factors in BRCA1-associated breast cancer. Annals of Oncology. 17(3). 391–400.
18.
Seynaeve, Caroline, et al.. (2003). Low Dose Methotrexate and Vinblastine, Given Weekly to PatientsWith Desmoid Tumours, is Associated With Major Toxicity. Sarcoma. 7(3-4). 153–157.
19.
Geel, Bert van, Sonja C. Henzen‐Logmans, Caroline Seynaeve, et al.. (2001). Breast Cancer after Prophylactic Bilateral Mastectomy in Women with aBRCA1orBRCA2Mutation. New England Journal of Medicine. 345(3). 159–164.
20.
Verweij, Jaap, Hans Herweijer, R. Oosterom, et al.. (1991). A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance. British Journal of Cancer. 64(2). 361–364.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Nadine Tung Breakdown of academic impact, for papers by Jennifer K. Litton Breakdown of academic impact, for papers by Claudine Isaacs Breakdown of academic impact, for papers by Lisa Cannon‐Albright Breakdown of academic impact, for papers by Patrick Neven Breakdown of academic impact, for papers by Ellen Warner Breakdown of academic impact, for papers by Kathleen E. Malone Breakdown of academic impact, for papers by Carl Blomqvist Breakdown of academic impact, for papers by Lucia Del Mastro Breakdown of academic impact, for papers by Tommy� Fornander